RRM2 (Gene)

Organism:

Homo sapiens

Synonyms:C2orf48, ENTREZ:6241, HGNC:10452, MIM:180390, NM_001034, NM_001165931, NP_001025, NP_001159403, NR_161344, NR_164157, R2, RR2, RR2M, RRM2, ribonucleotide reductase regulatory subunit M2

Omim:OMIM:180390

Nci:C26616

Id:ENSG00000171848

Hgnc:HGNC:10452

Entrez:6241

Ensembl:ENSG00000171848

Description:ribonucleotide reductase regulatory subunit M2

This gene encodes one of two non-identical subunits for ribonucleotide reductase. This reductase catalyzes the formation of deoxyribonucleotides from ribonucleotides. Synthesis of the encoded protein (M2) is regulated in a cell-cycle dependent fashion. Transcription from this gene can initiate from alternative promoters, which results in two isoforms that differ in the lengths of their N-termini. Related pseudogenes have been identified on chromosomes 1 and X. [provided by RefSeq, Sep 2009]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View RRM2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with RRM2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using RRM2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for RRM2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with RRM2.

Results found

Linked to

	Label	Description
	T60-Adrenal Consensus Gene Set (Entity type)	A Gene Set from MoTrPAC
	GSE89154 proscillaridin 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE171837 bortezomib 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 etoposide leukocyte 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE214505 AKR1B1 knockdown A-549 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE163297 doxorubicin 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226525 GSE226527 HNRNPH2 knockout 4 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 5 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 7 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151412 sorafenib 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

T60-Adrenal Consensus

Gene Set (Entity type)

A Gene Set from MoTrPAC

GSE89154 proscillaridin 1 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE171837 bortezomib 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE120612 etoposide leukocyte 7 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE214505 AKR1B1 knockdown A-549 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE163297 doxorubicin 0 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 4 v 8 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE115542 digoxin 5 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 7 v 9 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE151412 sorafenib 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.